


About SK life science

Established in 2002 and located in Paramus, New Jersey, SK Life Science, Inc., is committed to accelerating the development of innovative treatments for central nervous system (CNS) disorders. SK life science is a U.S. subsidiary of SK Biopharmaceuticals. Both SK life science and SK Biopharmaceuticals are a part of something bigger — SK Group, one of the largest conglomerates in Korea and a global leader in energy, chemical, semiconductor and telecommunications industries.



Our Vision

By taking on the mysteries of the brain, **we strive to make life better.**

Our pipeline sets the stage for success in CNS

SK Biopharmaceuticals and SK life science independently developed XCOPRI® from inception through to FDA approval. The treatment is being commercialized independently by SK life science in the U.S. SK Biopharmaceuticals also discovered, and after completing a phase I clinical trial, licensed-out a treatment for sleep disorders to Jazz Pharmaceuticals; this treatment ultimately received FDA approval. With this strong track record of research and discovery in CNS, the companies are continuing to explore new compounds that can address unmet patient needs. The companies have eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox-Gastaut syndrome and attention-deficit/hyperactivity disorder, among others.

COMPOUND	INDICATION	STATUS
Cenobamate	Epilepsy (Partial-Onset Seizures)	FDA approved EMA MAA accepted ¹
	Epilepsy (Primary Generalized Tonic-Clonic Seizures)	Phase 3
Solriamfetol ^{2,3}	Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea	FDA, EMA approved
Carisbamate	Lennox-Gastaut Syndrome	Phase 1b/2
Relenopride	Rare Neurological Disease	Phase 2
SKL13865	Attention Deficit/Hyperactivity Disorder	Phase I
SKL20540	Schizophrenia	Phase I
SKL-PSY ⁴	Bipolar Disorder	Phase I
SKL24741	Epilepsy	Phase I

¹ SK Biopharmaceuticals, the parent company of SK life science, out-licensed development and commercialization rights of cenobamate in Europe to Anville Therapeutics. The European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) Anville filed for cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures in adults.
² SK Biopharmaceuticals, the parent company of SK life science, out-licensed worldwide development and commercialization rights of solriamfetol, excluding certain jurisdictions in Asia, to Jazz Pharmaceuticals. Jazz received FDA and EMA approval.
³ SK Biopharmaceuticals maintains rights for 12 Asian markets.
⁴ Solriamfetol and SKL-PSY are developed only by SK Biopharmaceuticals, and not by SK life science.

Making a difference in epilepsy

Epilepsy is a condition of the brain characterized by seizures. Nearly 65 million people suffer from epilepsy worldwide, including 3.4 million people in the U.S.² The vast majority of people with epilepsy (60%) have partial onset-seizures, which begin in just one part of the brain.³

Having seizures is associated with debilitating and life-altering complications. Despite the availability of many anti-epileptic drugs, nearly 60% of patients with epilepsy continue to have seizures, many with more than three seizures per year, according to the Centers for Disease Control and Prevention.⁴

Epilepsy is associated with numerous complications, including:^{5,6,7}

	Risk of injury		Cognitive impairment
	Unemployment & underemployment		Poor quality of life
	Dependency		Sudden unexpected death in epilepsy (SUDEP)
	Depression & anxiety		

Our values define us

SK life science is defined by our values and driven by the unmet needs of patients, HCPs, caregivers and the CNS community. Our values are more than words on a page – they are what you can expect from us:

	Empower excellence		Embody a pioneering spirit
	Be fully engaged		Always do the right thing
	Appreciate & recognize people		Inspire happiness!

Leadership

With deep experience in drug development and commercialization in the U.S. and Korea, our leadership team is ready, willing and able to break conventions to address the unmet needs in CNS.

	Jeong Woo Cho, Ph.D. President & Chief Executive Officer		Sebbly Borriello Vice President & Chief Commercial Officer		Hong Wook Kim, Ph.D. Vice President & Chief Operating Officer		Marc Kamin, M.D. Vice President & Chief Medical Officer
--	--	--	--	--	---	--	---

Follow Us

@SKlifescience

SK Life Science, Inc.

Contact Us

General business
Info@sklsi.com

Strategic alliance & partnership opportunities
Partnerships@sklsi.com

Media inquiries & PR
Media@sklsi.com

¹ Cho Chung-un. SK likely to overtake Hyundai as Korea's 2nd-largest conglomerate. The Korea Herald. February 20, 2019. http://knews.heraldm.com/view.php?id=20190220000639&md=20190223003215_BL. Accessed October 2, 2019.
² CURE. What is epilepsy? <https://www.cureepilepsy.org/about-epilepsy/what-is-epilepsy>. Accessed October 2, 2019.
³ National Institute of Neurological Disorders and Stroke. The Epilepsies and Seizures: Hope through Research. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Epilepsies-and-Seizures-Hope-Through-Research#3109_9. Accessed October 2, 2019.
⁴ Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active Epilepsy and Seizure Control in Adults - United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep. 2018;67(15):437-442.
⁵ Epilepsy Foundation. Staying Safe. <https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe>. Accessed October 2, 2019.
⁶ Epilepsy Foundation. Challenges with Epilepsy. <https://www.epilepsy.com/learn/challenges-epilepsy>. Accessed October 2, 2019.
⁷ Epilepsy Foundation. Social Concerns. <https://www.epilepsy.com/learn/challenges-epilepsy/social-concerns>. Accessed October 2, 2019.